Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 11CNS 10Gastrointestinal 8Breast 5Head & Neck 4Sarcoma 3Genitourinary 3Other solid neoplasm 2Endocrine 2Tumor-Agnostic 1Other neoplasm 1NET 1

Conditions

Thyroid cancer, medullary 1Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × vandetanib × Endocrine × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡